Abbott Laboratories $ABT Shares Sold by First Financial Corp IN

First Financial Corp IN lowered its position in shares of Abbott Laboratories (NYSE:ABT) by 38.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,907 shares of the healthcare product maker’s stock after selling 5,614 shares during the quarter. First Financial Corp IN’s holdings in Abbott Laboratories were worth $880,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. McGlone Suttner Wealth Management Inc. increased its position in shares of Abbott Laboratories by 1.4% in the 3rd quarter. McGlone Suttner Wealth Management Inc. now owns 8,316 shares of the healthcare product maker’s stock valued at $822,000 after buying an additional 111 shares in the last quarter. Sivik Global Healthcare LLC raised its stake in Abbott Laboratories by 120.0% during the 3rd quarter. Sivik Global Healthcare LLC now owns 55,000 shares of the healthcare product maker’s stock worth $5,436,000 after buying an additional 30,000 shares during the period. Sax Wealth Advisors LLC lifted its holdings in Abbott Laboratories by 4.2% during the third quarter. Sax Wealth Advisors LLC now owns 7,341 shares of the healthcare product maker’s stock worth $725,000 after acquiring an additional 295 shares in the last quarter. NorthCrest Asset Manangement LLC grew its stake in Abbott Laboratories by 7.1% in the third quarter. NorthCrest Asset Manangement LLC now owns 61,010 shares of the healthcare product maker’s stock valued at $6,009,000 after acquiring an additional 4,065 shares during the period. Finally, Vertrix Wealth Management LLC grew its stake in Abbott Laboratories by 11.1% in the third quarter. Vertrix Wealth Management LLC now owns 32,631 shares of the healthcare product maker’s stock valued at $3,225,000 after acquiring an additional 3,254 shares during the period. Institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

ABT has been the subject of several recent analyst reports. Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target for the company in a report on Thursday, August 13th. UBS Group decreased their price objective on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Citigroup increased their target price on Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. BTIG Research increased their target price on Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Finally, JPMorgan Chase & Co. raised their target price on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $118.88.

Abbott Laboratories Stock Up 0.9%

NYSE ABT traded up $0.89 on Tuesday, reaching $102.71. The company had a trading volume of 9,863,158 shares, compared to its average volume of 11,308,400. The company’s fifty day moving average is $106.14 and its 200-day moving average is $98.29. The firm has a market capitalization of $177.72 billion, a price-to-earnings ratio of 33.24, a price-to-earnings-growth ratio of 1.85 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $133.34.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. The company’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter last year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Abbott Laboratories Profile

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.